Vir Biotechnology (NASDAQ:VIR – Get Free Report) and JATT Acquisition (NYSE:JATT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Analyst Ratings This is a breakdown of […]
Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as $12.10 and last traded at $12.15, with a volume of 320691 shares trading hands. The stock had previously closed at $12.51. Analysts Set New Price Targets Several equities research analysts have […]
Needham & Company LLC restated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research note released on Friday, Benzinga reports. They currently have a $22.00 price target on the stock. Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and set […]
Vir Biotechnology (NASDAQ:VIR – Get Free Report) released its earnings results on Thursday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.24), Briefing.com reports. The business had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $22.39 million. The company’s quarterly revenue […]